CellBio Scientific, a premier provider of life science tools, research services, and clinical solutions, announced the acquisition of BioChain, a leading provider of biospecimen collection, preparation, and analysis.
The acquisition strengthens CellBio Scientific's platform at a pivotal moment in drug discovery and development, as the industry focuses on using human-relevant research models and analyses. The combined platform will be well-positioned to meet growing demand for innovative tools and translational research solutions.
"BioChain has built a strong reputation over decades by delivering reliable, high-quality solutions to the global scientific and medical communities," said Charles Miller, CEO of CellBio Scientific. "This acquisition is highly complementary to our existing capabilities at System Biosciences and Acepix Biosciences. Together, we are building a unified platform that empowers discovery through scientific excellence, operational depth, and customer focus."
BioChain is widely recognized for its expertise in biological sample collection, preparation, and analysis, with a strong foundation in spatial genomics and biospecimen workflows. Its biospecimens are fully consented under IRB approval and products are routinely used by CLIA-certified laboratories, diagnostic test manufacturers, and translational research teams seeking high-quality, regulatory-compliant inputs.
"Joining CellBio Scientific allows BioChain to accelerate its impact while continuing to do what we do best—support life sciences innovation with trusted biospecimen and discovery solutions," said Grace Tian, CEO of BioChain. "This brings new opportunities to serve our customers and collaborate across a broader platform."
Comments powered by CComment